Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer Institute

Drug Profile

Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer Institute

Alternative Names: anti-KRAS-mutation; anti-SSX2 TCR; KITE-439; KITE-585; KRAS TCR; NEO Antigens; SSX2 TCR

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Antigen receptor antagonists; Cell replacements; Gene transference; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Jan 2017 Kite Pharma and Kite Pharma - Fosun Pharma (JV) enter into an option agreement to license KITE 439 and KITE 719 in China
  • 03 Jan 2017 Kite Pharma files an IND application with the USFDA for Solid tumours
  • 03 Jan 2017 Kite Pharma plans a phase I trial for Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top